Trial data suggest pain reduction exceeding 30% in approximately 50–65% of treated participants. However, CRPS exhibits marked placebo and natural variability effects, and no blinded sham-controlled trials with more than 50 participants have been completed. Real-world outcomes from uncontrolled clinics report higher perceived success rates (70–80%), though selection bias and loss-to-follow-up are substantial. Published efficacy evidence remains modest.
Two registered clinical trials are actively investigating stem cell interventions in CRPS populations. One multicentre trial examined intravenous allogeneic placental MSCs in 34 CRPS patients; preliminary results reported pain reduction (measured on 0–100 numerical rating scale) averaging 28–32 points at 12 weeks, compared to 8–12 points in sham controls. A second smaller trial of neurogenic precursor cells showed subjective functional improvement in hand dexterity tasks. Neither trial has reported long-term follow-up beyond 6 months. No major efficacy data have been published in peer-reviewed journals. Mechanistic research continues.
Sono un candidato? → · Complex Regional Pain Syndrome: full overview → · Costo Sindrome Dolorosa Regionale Complessa → · Cost →
Rivisto medicalmente dal team editoriale di StemCellAtlas con Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) della clinica partner Stem Plus (Sofia), rispetto alle linee guida ISSCR, FDA e EMA. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita